Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — FY2020 Earnings Presentation
17 slides from Aft Pharmaceuticals's earnings presentation, May 2020
Slide 1: Financial Year 2020 Results
Working to improve your health INVESTOR PRESENTATION MAY 2020 FINANCIAL YEAR 2020 RESULTS
Slide 2: Important Notice
Important Notice This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT for the financial year ended 31 March 2020. It is not prepared for any other purpose and must not be provided to any person other than the intended rec
Slide 3: Introduction to AFT
Introduction to AFT 120 10 year Operating Revenue CAGR of 14% 100 80 $m 60 40 20 - '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 '19 '20 INVESTOR PRESENTATION May 2020 • AFT Pharmaceuticals develops, licenses, and sells a range of medical products globally. • In Australasia, our product li
Slide 4: FY 2020 Highlights
FY 2020 Highlights 40% Increase in no. countries Maxigesic sold in to 28 24% Increase in operating revenue to NZ$105.6m 87% Increase in normalised operating profit1 to NZ$11.4m 229% NZ$5.3m INVESTOR PRESENTATION MAY 2020 Increase in normalized net profit after tax to $13.8m Increase in operating cas
Slide 5: Revenue Growth in Home and International Markets
Revenue Growth in Home and International Markets • Continued growth in established markets of Australia and NZ • Significant growth in Southeast Asia and Rest of World starting to come through post registration and distribution agreements FY2019 FY2020 FY2019 FY2020 50.3 61.4 50.0 60.0 2.5% 50.0 6.9
Slide 6: Financial performance - Revenue by region and channel
Financial performance - Revenue by region and channel NZ$000's FY2019 FY2020 10% Australia 50,304 59.1% 61,428 58.2% 26% YoY growth 12.6% 22.1% 64% 29% New Zealand 26,796 31.5% 30,108 28.5% 58% YoY growth 5.4% 12.4% 13% 16% 8% Rest of World 5,885 6.9% 9,131 8.6% INVESTOR PRESENTATION MAY 2020 YoY gr
Slide 7: Abbreviated Consolidated Income Statement
Abbreviated Consolidated Income Statement • Operating leverage starting to show as revenue continues to grow. Expenses largely falling as a % of revenue. NZ$'000's year ended 31 March 2020 % of 2019 % of revenue revenue Revenue 105,597 85,127 Gross Profit 48,265 45.7% 40,730 47.8% Underlying Operati
Slide 8: Abbreviated Balance Sheet
Abbreviated Balance Sheet • Replaced short term debt with longer term debt at more commercial rates • Significant increase in shareholders equity NZ$'000's year ended 31 March 2020 2019 Current assets 49,217 44,345 Cash 6,119 6,916 Non-current assets 31,716 12,334 Total assets 87,052 63,595 Current
Slide 9: Abbreviated Cashflow
Abbreviated Cashflow • Significant increase in operating cashflow NZ$'000's year ended 31 March 2020 2019 Net cash from operating activities 14,878 1,067 Net cash used in investing activities (6,562) (4,884) Net cash (used) / generated from financing activities (9,117) 3,723 INVESTOR PRESENTATION MA
Slide 10: Normalised Operating Profit progress
Normalised Operating Profit progress NZ$ million • Investment phase over FY15-18 showing large payback • Operating profit for FY21 expected to be in the range of NZ$14-18m 20 15 10 INVESTOR PRESENTATION MAY 2020 5 - '10 '11 '12 '13 '14 '15 (5) '16 '17 '18 '19 '20 $6m $11m '21 (10) $14m - $18m (15) 1
Slide 11: New Products build Revenue Pipeline
New Products build Revenue Pipeline Maxigesic IV registrations successfully completed – 21 countries (18 European, Australia, New Zealand, UAE) Maxigesic Oral Liquid registration underway in Europe, Australia and New Zealand Maxigesic Hot Drink Sachets registration underway December 2019 Maxigesic R
Slide 12: Maxigesic Global Update
MAXIGESIC GLOBAL UPDATE [primarily oral dose forms] titty eee ates ope es “Tauber pening 2000 ee “bt, akj i fits " ie e He at $343 em + Ucansing t ’ swtnder sa sit tte i f ie — Sees ees — — 4 Seems Fs toeaw al ae Sepltere ‘Italy - successful iaunch and ee a Sromtonnren ne ee eee dutriotor sppomtod u
Slide 13: Maxigesic around the world
Maxigesic around the world Belgium/Luxembourg – RX New Zealand – OTC Australia – OTC Italy – RX Launch pending 20 Launched Oct 09 Launched Feb 14 Launched April 15 CACM- OTC UAE – OTC Ireland – OTC Singapore/Malaysia Launched July 18 Launched Jan 15 Launched July 18 OTC launched June 18 Also sold in
Slide 14: Progress in global rollout of Maxigesic
Progress in global rollout of Maxigesic Product Maxigesic Tablets Maxigesic IV Maxigesic oral solution Territories 2020 2019 2020 2019 2020 2019 Licensed 125+ 125+ 80 68 122 122 Registered 44 42 3 - - - Sold in 28 20 - - - - INVESTOR PRESENTATION MAY 2020 14
Slide 15: Maxigesic Countries sold and ordered
Maxigesic Countries sold and ordered • Expecting a more than tripling of the number of countries Maxigesic is sold in over the next 2 years 140 120 100 80 60 INVESTOR PRESENTATION MAY 2020 125 40 20 66 2 43 0 3 4 7 20 FY14 9 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 15
Slide 16: Outlook
Outlook Further drive International Sales - Keep accelerating countries launched in - Launch new line extensions [Maxigesic IV] Extend International Licensing - Finalize licensing agreement discussions in China, Japan, LATAM and USA - Progress additional new territories added in FY2020: Canada, Chil
Slide 17: Working to improve your health
Working to improve your health